Skip to main content
Donate

Ovid Therapeutics Launches First Sponsored Clinical Trial For Angelman Syndrome

Ovid Therapeutics announces the first ever sponsored clinical trial for Angelman Syndrome. You first heard about Gabaxadol from Dr. Matthew During at the FAST 2014 Summit, now we have the exciting news that this sponsored clinical trial is moving forward. “We very much look forward to moving OV101 into the clinic, and hopefully making a difference in the lives of those with Angelman Syndrome and their families," stated Dr. Matthew During, President and Chief Scientific Officer of Ovid.  Read more about this announcement here…

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.